WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H561539
CAS#: 1391063-17-4
Description: PF-06651481-00, also known as Bosutinib Isomer I, is an analog of bosutinib, and a Bcr-Abl kinase inhibitor.
Hodoodo Cat#: H561539
Name: PF-06651481-00
CAS#: 1391063-17-4
Chemical Formula: C26H29Cl2N5O3
Exact Mass: 529.16
Molecular Weight: 530.450
Elemental Analysis: C, 58.87; H, 5.51; Cl, 13.37; N, 13.20; O, 9.05
Synonym: PF-06651481-00; PF 06651481 00; PF0665148100; Bosutinib Isomer I;
IUPAC/Chemical Name: 4-(3,5-Dichloro-4-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinoline-3-carbonitrile
InChi Key: YCLIWTLPTXAGPQ-UHFFFAOYSA-N
InChi Code: InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-24-14-22-19(13-23(24)34-2)25(17(15-29)16-30-22)31-18-11-20(27)26(35-3)21(28)12-18/h11-14,16H,4-10H2,1-3H3,(H,30,31)
SMILES Code: N#CC1=C(NC2=CC(Cl)=C(OC)C(Cl)=C2)C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 530.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Filppula AM, Neuvonen PJ, Backman JT. In vitro assessment of time-dependent
inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase
inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9. doi:
10.1124/dmd.114.057695. Epub 2014 Apr 8. PubMed PMID: 24713129.